# Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer

> **NCT02753881** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 30 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** whole liver lobe cTACE doxorubicin
- **DRUG:** superselective cTACE doxorubicin

## Key facts

- **NCT ID:** NCT02753881
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753881, "Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02753881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*